Dementia is a set of symptoms that include worsening of the routine of cognitive tasks, learning, reproducibility, and gait disturbances beyond typical aging. Activated c AMP can produce anti-apoptosis activity, neuroprotective activity, motor improvement, and cognitive enhancement activity. Cilostazol can increase c AMP levels, so this study aimed to evaluate the influence of cilostazol on learning-memory and motor coordination by rodent models. The rats were divided into 5 and 6 groups with 6 rats in each to test the hypothesis respectively. Before MES seizure induction the rats were trained for conditioned avoidance response for 14 days and the best one was selected for assessment. The performance of intervention treated groups to determine the memory retention effect was measured by applying a fixed number of shocks. The intervention treated groups were tested for motor coordination performance by rotarod test (4-45 RPM accelerating speed for 5 min) after 30 and 60 min. The latency time of each rat falls off from the rod for the first time was noted. The results were presented as Mean ± SD, tested by ordinary two way ANOVA followed by Tukey's multiple comparisons test. Cilostazol 100 mg/kg p.o demonstrated a significant memory enhancement activity in the conditioned avoidance response technique. Cilostazol 20mg/kg i.p alone and along with diazepam 2 mg/kg demonstrated a significant motor coordination performance in both sessions. The present study concludes that cilostazol has improved the learning & memory and motor coordination performances.

The present study is objected to evaluate the anticonvulsant activity of the phosphodiesterase III inhibitor cilostazol in the animal model of epilepsy. Conventional anti-epileptic rodent models like Maximal Electric Shock (MES)- induced convulsions and Pentylenetetrazol (PTZ) induced convulsions were used. The animals were randomly divided into six groups, with six rats in every group. Here anti-epileptic activity of cilostazol with two different doses (10 mg/kg i.p and 20 mg/kg i.p) was compared with standard drug and standard drug + Cilostazol two different doses (10 mg/kg i.p and 20 mg/kg i.p). Cilostazol (20 mg/kg i.p) exhibited an anticonvulsant effect in MES-induced and PTZ induced convulsion models over the Control group and cilostazol (10 mg/kg i.p). Standard drugs were shown superiority in seizure suppression activity than cilostazol (20 mg/kg i.p). The time duration of onset of clonic convulsion and period of clonic convulsions in PTZ induced convulsion were increased and decreased respectively when compared to Standard drug + cilostazol both doses and standard drug alone. Phenytoin abolished convulsions induced by MES- convulsion model. So the present study established that cilostazol has low anticonvulsant efficacy in comparison with conventional drugs (Phenytoin and Sodium Valproate). The potentiating effect of cilostazol with standard drugs was also demonstrated.

No abstract

The current anti-depressant agents have limitations like the slow onset of action, moderate efficacy, withdrawal symptoms, incompliance of treatment, and instabilities in circadian rhythm. Their therapeutic use is quite restricted and produces inadequate or partial symptomatic relief of depression which may lead to treatment- resistance depression. In the view of a new strategy, second messengers (cAMP, cGMP) and their signalling pathways are emerging as novel targets for anti-depressants. The present study conducted to evaluate the augmentation property of cilostazol on the anti-depressant activity of fluoxetine. Traditional anti-depressant models like forced swimming test and tail suspension test were employed. Mice were randomly grouped into six groups, with six rats in each. Each group was treated, as mentioned in the study. The reduction in immobility period of each mouse was noted. These results were analysed by ordinary one way ANOVA followed by Tukey’s multiple comparison test. Cilostazol at a dose of 20 mg/kg i.p significantly reduced immobility period when compared to cilostazol 10 mg/kg i.p and normal saline. Cilostazol 10 mg/kg i.p also decreased immobility period significantly when compared to normal saline by forced swimming test. Fluoxetine 20 mg/kg i.p + cilostazol 20 mg/kg i.p produced a highly significant reduction in the immobility period in comparison with all groups except with fluoxetine 20 mg/kg i.p + cilostazol 10 mg/kg i.p in forced swimming test. This study concludes that cilostazol has produced dose-dependent anti-depressant activity. This study also emphasises cilostazol can augment the anti-depressant activity of fluoxetine.